EMVision Medical Devices Limited provided an update on the progress of its clinical trial and its access to resources during the ongoing COVID-19 pandemic. At present, the Company is progressing the trial in line with its original six month timeline. To date, the COVID-19 pandemic, whilst affecting health care infrastructure and the wider community, has not impacted the enrolment rate of patients or the generation and processing of data necessary for the clinical trial. Nevertheless, the Company's ability to continue to progress the trial in accordance with its proposed timeframe will depend on its ability to continue to access resources, such as suitably qualified personnel, over the coming months. During the trial, the Company's primary objective is to collect imaging data from stroke patients that allows refinement and selection of the optimal imaging algorithms as well as early data on correlation of images generated by the Company's technology with CT and/or MRI imaging. The primary endpoint of EMVision's pilot clinical trial is to generate a dataset of stroke patient scans which improves the understanding of stroke on electromagnetic scattering effects in the brain. The single centre study will enrol 30 diagnosed stroke patients with confirmatory CT and/or MRI. No intervention or modification to the usual hospital-based treatment of stroke is proposed as part of this trial. To date, a significant number of the target 30 patients with different stroke subtypes have been enrolled and scanned in the study. Each patient has received multiple scans. Patients continue to be enrolled in the study. The datasets that have already been acquired provide the imaging algorithm and product development team with valuable learnings to continue the product development process. This includes the fine tuning of imaging algorithms and selection of the optimal "fusion" of advanced algorithms for planned commercial product. The Company intends to update the market with preliminary observations, images and results as soon as they are available. To manage the evolving COVID-19 situation, the Company has a number of risk mitigation processes in place. The trial team that is responsible for enrolling patients has multiple personnel redundancies built in. Within the team are several clinicians who have been trained in the operation of the EMVision brain scanner which allows for progress in the absence of some staff. The algorithm team are processing datasets remotely and continue to do so. The COVID-19 situation is dynamic and the Company will provide updates if there are any material changes to the progress of the trial.